Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholesterol Therapy Guidelines Stress Need To Consider Cost, Treat To Goal

Executive Summary

The National Cholesterol Education Program treatment guidelines encourage physicians to restrict drug therapy only to high risk patients - but expand the definition of high risk to include as many as 36 mil. people in the U.S.
Advertisement

Related Content

Merck/Schering Vytorin Launch Could Be Aided By New Cholesterol Guidelines
Merck/Schering Vytorin Launch Could Be Aided By New Cholesterol Guidelines
Statin Consumer Medication Guides Requested By HRG In Wake Of Baycol
Statin Consumer Medication Guides Requested By HRG In Wake Of Baycol
AstraZeneca To "Go It Alone" For Crestor, Cites Large Market Opportunity
Pravachol DTC Ads Promote NCEP Guidelines, Reps Focus On High Prescribers
Cholesterol Drugs May Be Good Candidates For Managed Care Pull Throughs
Cholesterol Combo Therapy Will Likely Be More Prominent In ATP IV
Andrx To Launch Lovastatin XL In 2002 With 150-Rep Sales Force
Andrx To Launch Lovastatin XL In 2002 With 150-Rep Sales Force
Advertisement
UsernamePublicRestriction

Register

PS037856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel